| Literature DB >> 31474356 |
Elizabeth K Lee1, Panagiotis A Konstantinopoulos2.
Abstract
Recent studies have demonstrated that, besides direct cytotoxic effects, poly(ADP ribose) polymerase (PARP) inhibitors (PARPis) exhibit antitumor immunity that occurs in a stimulator of interferon genes (STING)-dependent manner and is augmented by immune checkpoint blockade (CPB). In ovarian cancer, combined PARP and immune checkpoint inhibition has yielded encouraging preliminary results in two early-phase clinical trials and is currently being evaluated in both first-line and recurrent settings.Entities:
Keywords: PARP inhibitor; PD-1 inhibitor; STING pathway; checkpoint blockade; immunotherapy; ovarian cancer
Mesh：
Substances：
Year: 2019 PMID： 31474356 DOI： 10.1016/j.trecan.2019.06.004
Source DB: PubMed Journal: Trends Cancer ISSN： 2405-8025